EFFECT ·Filed Jun 26, 2026

KALA

KALA BIO, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed3mo ago SEC9999999995-26-002122
IPO/offering going effective
Actionable Insight ▼ Bearish

The effectiveness of this shelf, combined with two prior effective S-3s, creates a persistent dilution overhang. Monitor for any takedown announcements or registration statements that specify pricing — a large secondary could pressure the stock significantly given the small market cap.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
KALA ▼ -77.78% at T+60d
SHORT call ✓ call won +77.78% · α vs SPY +82.26% · entry $2.52 → $0.5600
Entry anchored
Jun 25, 03:55 PM ET
via exchange tick
T+1d
-17.06%
call +17.06% · α +18.71%
$2.09
settled 3mo ago
T+5d
-33.33%
call +33.33% · α +35.50%
$1.68
settled 3mo ago
T+20d
-75.78%
call +75.78% · α +77.04%
$0.6103
settled 2mo ago
T+60d
-77.78%
call +77.78% · α +82.26%
$0.5600
settled 10d ago

Price Chart

Loading chart...

Executive Summary

KALA BIO's shelf registration (File No. 333-295667) became effective on June 25, 2026, allowing the company to conduct offerings at any time. The underlying S-3 covers the resale of up to 241,435,910 shares of common stock by selling stockholders, primarily from preferred stock conversions and settlement agreements. This creates a substantial potential dilution overhang for a $47M market cap company.

Key Facts

  • Shelf registration effective June 25, 2026, under File No. 333-295667.
  • Covers resale of up to 241,435,910 shares of common stock by selling stockholders.
  • Shares include 12,000,010 Series AA conversion shares, 226,335,900 Series AAA conversion shares, 2,200,000 LifeSci settlement shares, and 900,000 Baker settlement shares.
  • Market cap is approximately $47M, making the potential dilution massive relative to current float.
  • Two prior S-3 filings (Feb 2026 and May 2026) also went effective, compounding the overhang.

Financial Impact

Potential dilution of up to 241.4M shares against a $47M market cap; no specific offering amount or pricing disclosed.

dilutionshare count

Risk Factors

  • Massive potential dilution from up to 241.4M registered shares relative to current float.
  • Multiple effective shelves increase the risk of near-term offerings.
  • Selling stockholders include large holders (Baker Bros., LifeSci) who may seek to exit.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (6 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002122
Document: 9999999995-26-002122-index.html9999999995-26-002122
Document: 9999999995-26-002122.txt9999999995-26-002122
5 reports for KALA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for KALA — sortable, filterable
TypeNow
Aug 28, 2026
5w ago
8-K
BEARISH ★ 8/10
$0.6901 $0.4502▲ +34.76%▲ +35.02%$0.3908 (+43.37%)
Jul 22, 2026
10w ago
424B5
BEARISH ★ 8/10
$0.6103 $0.8401▼ −37.65%▼ −34.35%$0.3908 (+35.97%)
Jun 26, 2026
14w ago
EFFECT
BEARISH ★ 7/10
$2.52 $0.6103▲ +75.78%▲ +77.04%$0.3908 (+84.49%)
May 7, 2026
21w ago
S-3
NEUTRAL ★ 2/10
$3.95 $2.06▼ −47.85%▼ −47.87%$0.3908 (−90.11%)
Mar 4, 2026
30w ago
Press Release
MIXED ★ 6/10
$17.25 $0.1630▼ −99.06%▼ −94.64%$0.3908 (−97.73%)
Showing 5 of 5

US Market Status

Market Open — Closes in 1h 30m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access